March 12, 2014 08:05 ET

MYOS Corporation to Present Abstract on Lipidomic and Proteomic Studies of MYO-T12® at the International Conference on Frailty and Sarcopenia Research

Abstract Supports Broad Therapeutic Indications for MYO-T12 to Treat Sarcopenia

CEDAR KNOLLS, NJ--(Marketwired - Mar 12, 2014) - MYOS Corporation (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance ("MYOS" or the "Company"), announced today that it has been selected to present the Company's abstract entitled "Lipidomic and Proteomic Studies of Fertilized Chicken Egg Yolk: Therapeutic Implications for Sarcopenia" at the International Conference on Frailty & Sarcopenia Research (ICFSR 2014) in Barcelona, Spain, being held March 13-14, 2014. 

The presentation on Thursday, March 13 will highlight the characterization of fertilized chicken egg yolk using advanced, cutting edge proteomic and lipidomic approaches. Fertilized chicken egg yolk is the source of active proteins in MYOS' commercial product, MYO-X™, powered by MYO-T12®, the first clinically proven bionutrition product shown to reduce serum myostatin levels. MYOS' proprietary technology is designed to optimize retention of the bioactivity of many proteins and lipids.

Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Reducing myostatin is believed to improve the health and performance of muscle tissue. The data from the lipidomic and proteomic study provide new insights into the possible mechanisms through which MYO-T12 exerts its beneficial effects on muscle and supports its strong potential as an effective treatment option for sarcopenia and frailty syndrome. MYOS expects to publish this research in the Journal of Frailty and Aging.

"MYOS has committed its research and development efforts to further characterizing other beneficial proteins, lipids and bioactive molecules found in MYO-T12," said Robert Ashton, M.D., MYOS' Chief Medical Officer. "The data from this latest research suggest potential novel therapeutic implications for the treatment of sarcopenia and frailty syndrome diseases that impact millions of elderly people throughout the world. Our proteomics and lipidomics research has identified proteins and lipids relevant to the formation of muscle tissue along with those with possible anti-inflammatory properties."

Sarcopenia is the degenerative loss of skeletal muscle mass (0.5 to 1% loss per year after the age of 25), quality and strength associated with aging and is a component of frailty syndrome. Frailty is highly prevalent in elderly people and confers high risk for falls, disability, hospitalization, and mortality. Frailty has been considered synonymous with disability, comorbidity, and other characteristics, but scientists and clinicians recognize that frailty may have a biological basis and could perhaps be a distinct clinical syndrome. Addressing frailty syndrome will be a key challenge in caring for aging baby-boomers. 

MYOS President and COO Peter Levy added, "As an emerging bionutrition and biotherapeutics company focused on muscle health, we are committed to developing therapeutic and nutritional products to improve muscle health and performance which will reduce the incidence of frailty among the aging baby-boomer population. We believe this has the potential to mitigate the enormous associated healthcare burden while improving the quality of life for elderly patients throughout the world."

About ICFSR 2014
The International Conference on Frailty and Sarcopenia 2014 - Implementing frailty and sarcopenia into clinical practice, is organized under the auspices of the Global Aging Research Network (GARN), a collaboration between the International Association of Gerontology and Geriatrics (IAGG) and the World Health Organization. The aim of GARN is to identify the best research centers dedicated to biological, behavioral, and clinical gerontology. For more information on ICFSR 2014 please visit and for additional information regarding sarcopenia please visit

About MYOS Corporation
MYOS is a developmental stage bionutrition and biotherapeutics company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of MYO-T12®, the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. For more information on MYO-T12 and to discover why MYOS is known as "The Muscle Company,"™ visit

The Company's first commercial product MYO-X™, powered by MYO-T12®, is distributed by Maximum Human Performance (MHP) and is currently available on popular retailer websites including, and in specialty retailers including GNC and Vitamin Shoppe and others. MYOS believes that MYO-X, as well as future products it envisions, will redefine existing standards for muscle health.

Forward-Looking Statements
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of MYO-T12® and its effects on myostatin inhibition, including our research and development activities described herein, product and customer demand, the continued growth of repeat purchases, market acceptance of our products, the ability to create new products through research and development, the continued growth in market expansion and revenue, the successful entry into new markets, the ability to attract additional investors and increase shareholder value, the ability to generate the forecasted revenue stream and cash flow from sales of MYO-X, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the continued growth and expansion of MYO-X in GNC, Vitamin Shoppe and other specialty retail stores, the ability to strengthen our manufacturing relationships and reduce the costs of our products, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Contact Information

  • Contact
    Jenene Thomas
    Investor Relations and Corporate Communications
    (973) 509-0444
    Email Contact